Coherus BioSciences Shares Climb 12% on FDA Approval for Cancer Treatment Loqtorzi

By Sabela Ojea Shares of Coherus BioSciences climbed 12% to $2.96 in after-hours trading after the company said the Food and Drug Administration approved...

Related Keywords

Sabela Ojea ,Coherus Biosciences ,Drug Administration ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Healthcare Life Sciences ,Biopharmaceuticals ,Regulation Government Policy ,Financial Performance ,New Products Services ,Product Service Approvals ,Corporate Industrial News ,Products Services ,Cancer ,Political General News ,Chemotherapy Radiotherapy Immunotherapy ,Respiratory Tract Diseases ,Health ,Respiratory Tract Cancer ,Medical Conditions ,Medical Treatments Procedures ,Content Types ,Factiva Filters ,C Amp Ampe Industry News Filter ,Synd ,Chrs ,Us19249h1032 ,Regulation ,Government Policy ,New Products ,Services ,Product ,Service Approvals ,Corporate ,Industrial News ,Products ,Political ,General News ,Chemotherapy ,Radiotherapy ,Immunotherapy ,Medical Treatments ,Procedures ,Healthcare ,Life Sciences ,